Antibe Therapeutics Inc. (ATE.TO)
Company Info
| ISIN | CA0370255097 |
|---|---|
| CUSIP | 037025509 |
| Sector | Healthcare |
| Industry | Medical Devices |
Highlights
| Market Cap | CA$23.70M |
|---|---|
| EPS | -CA$0.35 |
| Revenue (TTM) | CA$9.71M |
| Gross Profit (TTM) | CA$3.55M |
| EBITDA (TTM) | -CA$20.45M |
| Year Range | CA$0.30 - CA$1.23 |
| Target Price | CA$4.74 |
| Short % | 0.11% |
| Short Ratio | 0.02 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of CA$10,000 in Antibe Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Antibe Therapeutics Inc. had a return of -68.28% year-to-date (YTD) and -46.36% in the last 12 months. Over the past 10 years, Antibe Therapeutics Inc. had an annualized return of -27.57%, while the S&P 500 had an annualized return of 10.43%, indicating that Antibe Therapeutics Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -68.28% | 5.29% |
| 1 month | -30.59% | -2.47% |
| 6 months | -37.89% | 16.40% |
| 1 year | -46.36% | 20.88% |
| 5 years (annualized) | -38.11% | 11.60% |
| 10 years (annualized) | -27.57% | 10.43% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 8.60% | -4.95% | -53.12% | |||||||||
| 2023 | -7.55% | 40.82% | 7.25% | 25.68% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
Antibe Therapeutics Inc.(ATE.TO)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Antibe Therapeutics Inc. (ATE.TO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Antibe Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Antibe Therapeutics Inc. was 98.06%, occurring on Apr 1, 2024. The portfolio has not yet recovered.
The current Antibe Therapeutics Inc. drawdown is 96.53%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.06% | Mar 24, 2014 | 2515 | Apr 1, 2024 | — | — | — |
| -20% | Aug 22, 2013 | 80 | Dec 13, 2013 | 32 | Jan 31, 2014 | 112 |
| -12.94% | Mar 10, 2014 | 9 | Mar 20, 2014 | 1 | Mar 21, 2014 | 10 |
| -8.7% | Feb 18, 2014 | 6 | Feb 25, 2014 | 5 | Mar 4, 2014 | 11 |
| -6.9% | Jul 29, 2013 | 11 | Aug 13, 2013 | 6 | Aug 21, 2013 | 17 |
Volatility
Volatility Chart
The current Antibe Therapeutics Inc. volatility is 111.91%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |